ORIC
Oric Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$914.06M
P/E Ratio
—
EPS
$-1.39
Beta
1.10
52W High
$14.93
52W Low
$4.63
50-Day MA
$10.75
200-Day MA
$10.93
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-148.72M |
| Operating Margin | 0.00% |
| Return on Equity | -42.60% |
| Return on Assets | -27.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.90 |
| Price-to-Book | 2.20 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $103.52M |
| Float | $70.73M |
| % Insiders | 6.42% |
| % Institutions | 117.11% |
Analyst Ratings
Consensus ($20.77 target)
2
Strong Buy12
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/14/2026